Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term phase-i. Found 24 abstracts

no pagination
Wang SZ, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunology Immunotherapy. 2012 Jan;61(1):49-61.   PMCID: PMC3517883
Robinson MK, Alpaugh RK, Borghaei H. Naptumomab estafenatox: a new immunoconjugate. Expert Opinion on Biological Therapy. 2010 Feb;10(2):273-9.   PMCID: not NIH funded
Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin DH, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin. Journal of Thoracic Oncology. 2009 Nov;4(11):1397-403.   PMCID: PMC2941876
Lewis-Wambi JS, Swaby R, Kim H, Jordan VC. Potential of L-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 2009 Mar;114(1-2):33-9.   PMCID: PMC28689080
Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. JOURNAL OF CLINICAL ONCOLOGY. 2006 Oct;24(29):4764-74.
Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, Zhang CF, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). JOURNAL OF CLINICAL ONCOLOGY. 2006 Mar;24(9):1395-403.
de Jongh FE, Gallo JM, Shen MY, Verweij J, Sparreboom A. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemotherapy and Pharmacology. 2004 Aug;54(2):105-12.
Gaskin DJ, Weinfurt KR, Castel LD, DePuy V, Li Y, Balshem A, Benson A, Burnett CB, Corbett S, Marshall J, Slater E, Sulmasy DR, Van Echo D, Meropol NJ, Schulman KA. An exploration of relative health stock in advanced cancer patients. Medical Decision Making. 2004 Nov;24(6):614-24.
Ho DH, Covington W, Brown N, Lin SN, Pazdur R, Huo YY, Creaven PJ, Rustum YM, Meropol NJ, Lassere Y, Kuritani J, Hayakawa T. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. Cancer Chemotherapy and Pharmacology. 2000 Nov;46(5):351-6.
Ozols RF. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Seminars in Oncology. 1999 Feb;26(1):84-9.
Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy. Current Opinion in Immunology. 1999 Oct;11(5):558-62.
Bookman MA. Biological therapy of ovarian cancer: Current directions. Seminars in Oncology. 1998 Jun;25(3):381-96.
Hermann JF, Ettinger DS, Gams R. The final dilemma - End-of-life treatment decisions. Cancer Practice. 1998 Jan;6(1):57-9.
Morgan AS, Sanderson PE, Borch RF, Tew KD, Niitsu Y, Takayama T, Von Hoff DD, Izbicka E, Mangold G, Paul C, Broberg U, Mannervik B, Henner WD, Kauvar LM. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Research. 1998 Jun 15;58(12):2568-75.
Schilder RJ, Shea TC. Multiple cycles of high-dose chemotherapy for ovarian cancer. Seminars in Oncology. 1998 Jun;25(3):349-55.
Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center Study 94-001. Seminars in Oncology. 1997 Aug;24(4):89-95.
Devineni D, Gallo JM. Zalcitabine - Clinical Pharmacokinetics and Efficacy. Clinical pharmacokinetics. 1995 May;28(5):351-60.
Lacreta FP, Brennan JM, Nash SL, Comis RL, Tew KD, Odwyer PJ. Pharmacokinetics and Bioavailability Study of Ethacrynic-Acid as a Modulator of Drug-Resistance in Patients with Cancer. Journal of Pharmacology and Experimental Therapeutics. 1994 Sep;270(3):1186-91.
Oboyle KP, Mattes MJ, Sigurdson ER, Sutantoward E, Divgi CR, Welt S, Wright KE. Localization of Complement-Fixing Cytotoxic Monoclonal- Antibodies to Subcutaneous Tumors and Liver Metastases in a Syngeneic Immunocompetent Rat Colon-Carcinoma Model. Journal of Immunotherapy. 1994 Apr;15(3):175-84.
Odwyer PJ, Lacreta FP, Haas NB, Halbherr T, Frucht H, Goosenberg E, Yao KS. Clinical, Pharmacokinetic and Biological Studies of Topotecan. Cancer Chemotherapy and Pharmacology. 1994 Aug;34:S46-S52.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term phase-i

phase-i oncology-group expression inhibition cell-lines pharmacodynamics colony-stimulating factor Oncology carcinoma survival tumor-cells monoclonal-antibody cell lung-cancer trial chemotherapy irinotecan gene cyclophosphamide modulation NSCLC i clinical-trials activation bispecific monoclonal- efficacy gd3 missense mutation cells phase I trials renal cell carcinoma factor-i glutathione-s-transferase Toll-like receptor 4 agonist 871 CP-751 receptor SEA tamoxifen gene-expression bone-marrow transplantation ethacrynic-acid randomized trial clinical trials unchanged cisplatin line clinical-trial melphalan fluorouracil plus leucovorin risk stage-iii pancreatic cancer disposition binding protein-3 life intrahepatic infusion cyto-toxicity intraarterial floxuridine anti-cd20 monoclonal-antibody nephrotoxicity transgenic mice htlv-iii tumor-necrosis-factor cancer Ftorafur(tegafur) dose-escalation immunotherapy infectivity intraperitoneal treatment topoisomerase-i inhibitor anti-target cell pneumonia 5-fluorouracil topotecan syngeneic bd ix rats aids-related complex activated killer-cells carboplatin thymidylate synthase mustards platinum acquired immunodeficiency mesylate leukemic-cells oral topotecan immunodeficiency-virus-infection t-lymphotropic retrovirus conjugation attitudes uft intensive therapy colorectal-carcinoma perceptions toxicity lymphocytes ganglioside gst-pi-gene cytokines intravenous cisplatin prognostic factors topoisomerase-i inhibitors receptor agonists superantigen lymphoma tyrosine kinase camptothecin support recombinant gamma-interferon pneumocystis-carinii 871 monoclonal-antibody cp-751 hyperfractionated radiation-therapy alkylating-agents kit mutations estrogen deprivation nitrogen resistance antibodies UFT cpt-11 blood progenitor cells chlorambucil overdose control tumor-therapy patient preferences immunocompetence patient rfb4(dsfv)-pe38 thiotepa topoisomerase i expression renal-cell paclitaxel acquired-resistance naptumomab immunotoxin proteins 5t4 oncofetal antigen complement single-chain fv radiotherapy rat Transgenic mouse Figitumumab advanced solid tumors homosexual men HER2 ovarian-carcinoma surface escherichia-coli fc-gamma-ri fluorouracil physicians 5-FU circulating
Last updated on Friday, August 14, 2020